GTX INC Intellectual Property Contracts & Agreements
24 Contracts & Agreements
- License Agreements (24 contracts)
- Amended and Restated License Agreement between Oncternal Oncology, Inc. and The Regents of the University of California dated August 6, 2024 (Filed With SEC on August 8, 2024)
- Second Amendment to the UTRF License Agreement dated March 4, 2024 (Filed With SEC on March 7, 2024)
- Amendment #4 to the Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and UC San Diego dated August 31, 2018 (Filed With SEC on January 23, 2024)
- First Amendment to the Amended and Restated License Agreement Between the University of Tennessee Research Foundation and the Registrant dated August 22, 2022 (Filed With SEC on November 3, 2022)
- Amended and Restated License Agreement between the University of Tennessee Research Foundation and the Registrant Oncternal Therapeutics, Inc. dated March 9, 2022 (Filed With SEC on March 10, 2022)
- Amendment #3 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated February 5, 2021 (Filed With SEC on March 11, 2021)
- Amendment #2 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated May 15, 2019 (Filed With SEC on March 16, 2020)
- Amendment No. 1 to Commercial License Agreement between Selexis SA and Oncternal Therapeutics, Inc., dated February 7, 2020 (Filed With SEC on March 16, 2020)
- Amendment #1 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated March 25, 2019 (Filed With SEC on April 8, 2019)
- Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and The Regents of the University of California, dated August 31, 2018 (Filed With SEC on April 8, 2019)
- License Agreement between Oncternal Therapeutics, Inc. and Velos Biopharma Holdings, LLC, dated February 6, 2018 (Filed With SEC on April 8, 2019)
- Amendment to Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 17, 2016 (Filed With SEC on April 8, 2019)
- Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 26, 2014 (Filed With SEC on April 8, 2019)
- Commercial License Agreement between Selexis SA (predecessor to Oncternal Therapeutics, Inc.) and ROAR Therapeutics, LLC, dated May 19, 2014 (Filed With SEC on April 8, 2019)
- Amendment #4 to the License Agreement, as amended, dated October 23, 2018, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Amendment #3 to the License Agreement, as amended, dated April 6, 2017, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Amendment #2 to the License Agreement, as amended, dated August 12, 2016, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- Amendment #1 to the License Agreement, dated November 12, 2015, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- License Agreement, effective March 1, 2015, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)
- EX-10.41 Amended and Restated License Agreement (Filed With SEC on November 9, 2007)
- EX-10.40 Consolidated, Amended, License Agreement (Filed With SEC on November 9, 2007)
- Ex-10.15 Amended License & Supply Agreement (Filed With SEC on March 9, 2007)
- Ex-10.36 Partial Assignment of License & Supply Agreement (Filed With SEC on November 3, 2006)
- Ex-10.2 Amended and Restated License Supply Agreement (Filed With SEC on March 7, 2005)
